• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Crosstalk between TBK1/IKK ε and the type 1 interferon pathway contributes to tubulointerstitial inflammation and kidney tubular injury
In conclusion, T1-IFNs, TWEAK, and LPS engage interrelated proinflammatory and antiviral responses in tubular cells. Moreover, inhibition of TBK1/IKKε with amlexanox, and IFNAR targeting, may protect from tubulointerstitial kidney injury.
Source: Frontiers in Pharmacology - September 23, 2022 Category: Drugs & Pharmacology Source Type: research

Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
ConclusionsThese findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.
Source: Pharmaceutical Research - February 15, 2022 Category: Drugs & Pharmacology Source Type: research

Design and Invitro Characterization of Green Synthesized Magnetic Nanoparticles Conjugated with Multitargeted Poly Lactic Acid Copolymers for Co-delivery of siRNA and Paclitaxel
CONCLUSION: Conjugation of both folic acid and T7-peptide on the surface of micelles compared to separate conjugation of one of these ligands, increased the efficiency of drug and siRNA delivery to breast cancer cells.PMID:34520835 | DOI:10.1016/j.ejps.2021.106007
Source: European Journal of Pharmaceutical Sciences - September 14, 2021 Category: Drugs & Pharmacology Authors: Amin Amani Mohammad Dustparast Mehran Noruzpour Rasool Asghari Zakaria Hossein Ali Ebrahimi Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Yinxue Song, Bin Zhou, Xiangyang Du, Yong Wang, Jie Zhang, Yanqiu Ai, Zongjiang Xia, Gaofeng Zhao
Source: Biomedicine and Pharmacotherapy - February 25, 2020 Category: Drugs & Pharmacology Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy
In this study, we demonstrate the use of lipids as co-surfactants for the preparation of mixed micelles to improve the siRNA delivery of cholic acid-based block copolymers. Poly(allyl glycidyl ether) (PAGE) and poly(ethylene glycol) (PEG) were polymerized on the surface of cholic acid to afford a star-shaped block copolymer with four arms (CA-PAGE-b-PEG)4. The allyl groups of PAGE were functionalized to bear primary or tertiary amines and folic acid was grafted onto the PEG chain end to increase cell uptake. (CA-PAGE-b-PEG)4 functionalized with either primary or tertiary amines show high siRNA complexation with close to 10...
Source: International Journal of Pharmaceutics - January 26, 2020 Category: Drugs & Pharmacology Source Type: research

New approaches to tumour therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles.
Conclusions: The formulation we developed is a potential carrier system for both treatment of cancer and prevention of pain, especially for metastatic cancers. PMID: 31491363 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - September 8, 2019 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

Current Development of siRNA Bioconjugates: From Research to the Clinic
In this study, it was shown that the main factor determining the nature of the biodistribution of conjugates is their lipophilicity. Conjugates of siRNA with lower lipophilicity; i.e., derivatives of retinoic acid, lithocholic acid, and docosahexanoic acid with greater efficiency than cholesterol conjugates accumulated in the kidneys, bladder, and lungs of the mouse after subcutaneous injection (Biscans et al., 2018). This fact is consistent with previous data that showed that more lipophilic conjugates bind more efficiently to serum components, and thus are not excreted by the kidneys (Wolfrum et al., 2007; Osborn et al.,...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl- β-Cyclodextrin Conjugate
AbstractWe have previously reported the utility of folate-polyethylene glycol-appended dendrimer conjugate with glucuronylglucosyl- β-cyclodextrin (Fol-PEG-GUG-β-CDE) (generation 3) as a tumor-selective carrier for siRNA against polo-like kinase 1 (siPLK1)in vitro. In the present study, we evaluated the potential of Fol-PEG-GUG- β-CDE as a carrier for the low-molecular antitumor drug doxorubicin (DOX). Further, to fabricate advanced antitumor agents, we have prepared a ternary complex of Fol-PEG-GUG-β-CDE/DOX/siPLK1 and evaluated its antitumor activity bothin vitro andin vivo. Fol-PEG-GUG- β-CDE released DOX in an aci...
Source: The AAPS Journal - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study.
This study is aimed at developing and evaluating the safety and efficiency of siRNA delivery using unmodified and folic acid (FA) modified poly(amidoamine) generation 5 (PAMAM G5D) functionalized gold nanoparticles (Au:G5D/Au:G5D:FA) in vitro. All formulations were physico--chemically characterized and nanocomplexes were evaluated using the band shift, dye displacement, nuclease protection, MTT cell viability, and luciferase reporter gene assays. Nanocomplexes bound and protected siRNA against degrading RNases, and were well tolerated by the cells. The Au:G5D:FA nanocomplexes elicited excellent gene silencing in folate rec...
Source: Acta Pharmaceutica - February 28, 2019 Category: Drugs & Pharmacology Authors: Mbatha LS, Maiyo FC, Singh M Tags: Acta Pharm Source Type: research

Pages: 1  2